LID Clinical Studies Unit
Alison Han, M.D., MS
Specialty(s): Infectious Disease, Internal Medicine, Pediatrics Provides direct clinical care to patients at NIH Clinical Center
Major Areas of Research
- Screening healthy volunteers for challenge and vaccine studies
- Influenza and other respiratory virus challenge models
- Transmission of influenza and other respiratory viruses
- Influenza, COVID-19, and other respiratory virus immunity in children and adults
- Norovirus pathogenesis and experimental treatments for chronic norovirus
The LID Clinical Studies Unit (CSU) has validated influenza challenge models that have been used to better understand influenza pathogenesis and to evaluate potential vaccines and therapeutics. In addition, we have several natural history studies to understand short and long-term immunity after influenza challenge and after vaccination. The LID CSU has collaborated with research groups to develop and implement clinical protocols to explore the pathogenesis and evaluation of novel vaccines and therapeutics for other important infectious diseases, including vector borne diseases and diarrheal diseases, such as norovirus.
M.S., Harvard T. H. Chan School of Public Health
M.D., Morehouse School of Medicine
Alison Han completed her undergraduate degree at Emory University and received a Master of Science degree from Harvard T. H. Chan School of Public Health. She received her M.D. from Morehouse School of Medicine and completed a residency in internal medicine and pediatrics at University Hospitals Case Medical Center/Rainbow Babies and Children’s Hospital in Cleveland, Ohio. She completed infectious diseases fellowship at the National Institutes of Health (NIH) and then joined the LID Clinical Studies Unit first as a fellow and then as a staff clinician.
Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine, NCT05027932
Natural History of Systemic and Nasal Mucosal Immunity after Influenza Vaccination in a Pediatric Population, NCT04963166
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults after Vaccination, NCT04794829
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts, NCT04691622
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies, NCT04772170
Long-Term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge, NCT02511002
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols, NCT01386424
Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Xiao Y, Gouzoulis M, Lumbard K, Hunsberger S, Reed S, Athota R, Baus HA, Lwin A, Sadoff J, Taubenberger JK, Memoli MJ. Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model. Clin Infect Dis. 2021 Dec 6;73(11):e4260-e4268.
Park JK, Xiao Y, Ramuta MD, Rosas LA, Fong S, Matthews AM, Freeman AD, Gouzoulis MA, Batchenkova NA, Yang X, Scherler K, Qi L, Reed S, Athota R, Czajkowski L, Han A, Morens DM, Walters KA, Memoli MJ, Kash JC, Taubenberger JK. Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model. Nat Med. 2020 Aug;26(8):1240-1246.
Manning JE, Oliveira F, Coutinho-Abreu IV, Herbert S, Meneses C, Kamhawi S, Baus HA, Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Athota R, Reed S, Mateja A, Hunsberger S, James E, Pleguezuelos O, Stoloff G, Valenzuela JG, Memoli MJ. Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial. Lancet. 2020 Jun 27;395(10242):1998-2007.
Han A, Czajkowski LM, Donaldson A, Baus HA, Reed SM, Athota RS, Bristol T, Rosas LA, Cervantes-Medina A, Taubenberger JK, Memoli MJ. A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model. Clin Infect Dis. 2019 Nov 27;69(12):2082-2090.
Han A, Poon JL, Powers JH 3rd, Leidy NK, Yu R, Memoli MJ. Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model. BMC Infect Dis. 2018 Jul 28;18(1):353.
Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT Jr, Taubenberger JK. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. mBio. 2016 Apr 19;7(2):e00417-16.